Bleeker, J.C., et al., Ketonesters as a Possible Novel Therapeutic Option for Patients With Fatty Acid Oxidation Disorders [abstract]
To maximise benefits, consider forms that offer better absorption, such as liposomal or sublingual glutathione
INP-027/2020-Program E022 also supported this work
Chen KW, Boyko EJ, Bergstrom RW et al (1995) Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM
Restraint Supply shortages and compounding restrictions Australia is facing widespread shortages of GLP-1 receptor agonists such as semaglutide (Ozempic) and dulaglutide (Trulicity), since late 2022 and has been a major issue which is due to growing demand surpassing production, further affecting type 2 diabetes care, cardiovascular risk reduction and weight management in patients
Discussion The population pharmacokinetic model reported here successfully describes the pharmacokinetics of semaglutide, reproducing the values for CL/F and V/F of approximately 0.05 l/h and 12.5 l, respectively, obtained from clinical pharmacology trials with richly sampled PK profiles in subjects with T2DM (Novo Nordisk, data on file)
